Post by icemandios on Jun 28, 2023 13:04:48 GMT
Aspira Women's Health, Inc. Received A $1 MM Loan Forgiveness And 6-Month Payment Deferral From The CT DECD
AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (“DECD”) has determined that Aspira satisfied all job creation and retention requirements under the loan agreement entered into by the Company and DECD in 2016. As a result, Aspira is entitled to a credit of $1,000,000 towards its outstanding loan balance. Following the loan forgiveness, the Company’s total outstanding debt obligations will be approximately $1.6 million. In a separate agreement, the DECD agreed to defer all principal and interest payments due under all outstanding loan agreements until December 1, 2023.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.
Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite SM . OvaWatch SM is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus ® combines our FDA-cleared products, Ova1 ® and Overa ® , to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.
EndoCheck™, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com .